Items tagged with Drug-resistant TB
RESIST-TB September 2023 newsletter (post)
RESIST-TB released its September 2023 newsletter with the latest updates and research publications on drug-resistant TB.
Study aims to shorten diagnosis for drug-resistant TB (post)
Drug-resistant tuberculosis (DR-TB) is a global health threat due to high mortality, cost of treatment and risk of transmission. In 2021, there were an estimated 450 000 cases of DR-TB worldwide and 191 000 deaths. South Africa has one of the highest numbers of drug-resistant patients globally, but shockingly only 50% of these patients are started on treatment.
Kyrgyzstan, Ukraine, and Uzbekistan update national guidelines for drug-resistant TB treatment to advance national rollout of three-drug, six-month regimen (post)
PRETORIA (September 18, 2023)—Kyrgyzstan, Ukraine, and Uzbekistan – participants in the LIFT-TB project – have updated their National Tuberculosis (TB) Clinical Guidelines to endorse the all-oral, six-month BPaL/M (bedaquiline + pretomanid + linezolid ± moxifloxacin) regimen(s) as the national standard for treating most patients with drug-resistant tuberculosis (DR-TB).
Unitaid to partner with communities and civil society to drive access to new drug-resistant TB treatment regimens with new call for proposals (post)
Geneva, 20 September 2023 – As the United Nations General Assembly convenes world leaders at the High-Level Meeting on Tuberculosis (TB) this week, discussions will focus on the urgent need for access and innovation to put an end to a disease that we have known how to cure for decades. Despite this, TB continues to kill more people each year than any other infectious disease.
Patients’ rights groups accuse Union health ministry of denying shortages of key medicines for drug-resistant TB (post)
Patients’ rights groups have accused the Union health ministry of denying shortages of key medicines for drug-resistant tuberculosis (TB) even though they say the ministry’s own figures of drug inventories indicate why patients are facing shortages.
Very poor long-term outcomes for people with TB and HIV in Eastern Europe (post)
The rates of tuberculosis (TB) recurrence and mortality in people with HIV in eastern Europe remain concerningly high and continue to be a clinical and public health challenge, according to a paper published in AIDS. In the first study to report on long-term follow-up of TB/HIV co-infected patients in eastern Europe, one in seven people had TB again and over half died.
RESIST-TB October 2023 newsletter (post)
RESIST-TB released its October 2023 newsletter with the latest updates and research publications on drug-resistant TB.
Johnson & Johnson lifts patent on MDR-TB drug but it may be years before South Africa benefits (post)
Pharmaceutical giant Johnson & Johnson (J&J) recently announced that it would lift patents on the life-saving drug bedaquiline.
Life-saving TB drug is now cheaper in South Africa, but not as cheap as it can be (post)
The South African government and pharmaceutical company Johnson & Johnson (J&J) have agreed to a lower price for bedaquiline, a medicine used to treat drug-resistant tuberculosis (DR-TB) in South Africa.
Post-treatment recurrence risk low for multidrug-resistant TB (post)
There was a low risk for post-treatment recurrence among patients who received treatment for multidrug- or rifampicin-resistant tuberculosis infection.
Page 82 of 117 · Total posts: 0
←First 81 82 83 Last→